Bloomberg Anywhere Remote Login Bloomberg Terminal Request a Demo

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $3.85 USD
Change Today -0.01 / -0.26%
Volume 98.9K
OCRX On Other Exchanges
Symbol
Exchange
Frankfurt
As of 8:10 PM 09/3/15 All times are local (Market data is delayed by at least 15 minutes).

ocera therapeutics inc (OCRX) Snapshot

Open
$3.90
Previous Close
$3.86
Day High
$3.91
Day Low
$3.77
52 Week High
11/28/14 - $8.10
52 Week Low
04/30/15 - $3.30
Market Cap
76.6M
Average Volume 10 Days
63.4K
EPS TTM
$-1.27
Shares Outstanding
19.9M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for OCERA THERAPEUTICS INC (OCRX)

Related News

No related news articles were found.

ocera therapeutics inc (OCRX) Related Businessweek News

No Related Businessweek News Found

ocera therapeutics inc (OCRX) Details

Ocera Therapeutics, Inc. operates as a clinical stage biopharmaceutical company. It focuses on the development and commercialization of OCR-002, which is in Phase IIb trials for the treatment of hyperammonemia and hepatic encephalopathy in patients with liver cirrhosis, acute liver injury, and acute liver failure, as well as in the areas of unmet medical need. The company is headquartered in Palo Alto, California.

16 Employees
Last Reported Date: 03/13/15

ocera therapeutics inc (OCRX) Top Compensated Officers

Chief Executive Officer, President, Secretary...
Total Annual Compensation: $425.0K
Chief Business Officer
Total Annual Compensation: $213.5K
Compensation as of Fiscal Year 2014.

ocera therapeutics inc (OCRX) Key Developments

Ocera Therapeutics, Inc. Announces Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2015

Ocera Therapeutics, Inc. announced unaudited consolidated earnings results for the second quarter and six months ended June 30, 2015. For the quarter, the company reported total revenue of USD 43,000 against USD 33,000 a year ago. Loss from operations was USD 6,247,000 against USD 7,255,000 a year ago. Net loss from continuing operations was USD 6,221,000 against USD 7,243,000 a year ago. Net loss was USD 6,221,000 against USD 7,223,000 a year ago. Net loss per share from continuing operations- basic and diluted was USD 0.31 against USD 0.46 a year ago. Total net loss per share- basic and diluted was USD 0.31 against USD 0.46 a year ago. For the six months, the company reported total revenue of USD 74,000 against USD 78,000 a year ago. Loss from operations was USD 12,911,000 against USD 12,450,000 a year ago. Net loss from continuing operations was USD 12,872,000 against USD 12,425,000 a year ago. Net loss was USD 11,288,000 against USD 2,818,000 a year ago. Net loss per share from continuing operations- basic and diluted was USD 0.65 against USD 0.80 a year ago. Total net loss per share- basic and diluted was USD 0.65 against USD 0.73 a year ago.

Ocera Therapeutics, Inc. Secures $20 Million Debt Facility from Oxford Finance and Silicon Valley Bank

Ocera Therapeutics, Inc. announced that it secured a $20 million debt facility from Oxford Finance LLC (Oxford) and Silicon Valley Bank (SVB). Ocera intends to use the additional capital to support the ongoing development of the company's novel molecule OCR-002 to treat acute and chronic patients with hepatic encephalopathy. Under the terms of the two-tranche loan agreement, the company received $10 million upon closing on July 30, 2015, with the remaining $10 million available for draw until December 31, 2016. The facility is in the form of a secured note, which is repayable in interest only installments over 18 months, with a 6 month extension upon the drawing of the second tranche. The note bears interest at a rate fixed at the funding date of each tranche.

Ocera Therapeutics, Inc. Announces Executive Changes

Ocera Therapeutics, Inc. announced that effective on June 18, 2015, Jean-Paul Castaigne, M.D. and Lars G. Ekman, M.D., Ph.D., who did not stand for reelection at the annual meeting, ceased to be members of the company's board of directors, and the size of the board was reduced to seven directors. Eckard Weber, M.D. was appointed to the Audit Committee of the board of and Nina Kjellson was appointed to the Compensation Committee of the board, each replacing Dr. Castaigne.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
OCRX:US $3.85 USD -0.01

OCRX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for OCRX.
View Industry Companies
 

Industry Analysis

OCRX

Industry Average

Valuation OCRX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 226.5x
Price/Book 1.9x
Price/Cash Flow NM Not Meaningful
TEV/Sales 105.5x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact OCERA THERAPEUTICS INC, please visit www.ocerainc.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.